Prenatal exposure to psychoactive substances: Results of "NENUPHAR" study;Exposition in utero à des substances psychoactives: Résultats de l'étude «NENUPHAR»

Therapie

Volumn 62, Issue 2, 2007, Pages 177-183

  Lacroix, Isabelle ^a   Hurault, Caroline ^a   Saivin, Sylvie ^a   Raoul, Valérie ^a   Berrebi, Alain ^b   Souchet, Emmanuelle ^a   Desboeuf, Karine ^c   Montastruc, Jean Louis ^a   Damase Michel, Christine ^a  

^a Service de Pharmacologie Clinique   (France)

^b Paul Sabatier University   (France)

^c Hotel Dieu   (France)

Author keywords

Neonatal disease; Neonatal withdrawal; Newborn; Pregnancy; Psychoactive drugs

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; NEWBORN; NEWBORN DISEASE; PREGNANCY; PRENATAL EXPOSURE; RETROSPECTIVE STUDY;

FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MATERNAL EXPOSURE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 34548632375     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie:2007030     Document Type: Article

References (20)

1. Di-Meglio JL, Lacroix I, Bourrel R, et al. Prescription of psychoactive drugs during pregnancy in France. Fund Clin Pharmacol 2005; 19: 224 [abstract]
2. Kintz P, Tracqui A, Mangin P. Tobacco, drug and narcotic abuse during pregnancy. Evaluation of in utero exposure by analysis of hair of the neonate. Presse Med 1992; 21: 2139-41
3. Chasnoff IJ. Drug use in pregnancy: mother and child. Lancaster: MTP press, 1986
4. Finnegan LP, Emich JP, Connangton JF. Abstinence score in the treatment of the infants of drug dependent mothers. Pediatr Res 1973; 7: 319-26
5. http://www.sante.gouv.fr/htm/dossiers/perinat03/sommaire.htm
6. OFDT. Drogues et dépendances, données essentielles (2005). Paris : La découverte, 2005
7. Beck F, Legleye S, Spilka S, et al. Les niveaux d'usage des drogues en France en 2005, exploitation des données du Baromètre santé 2005. Tendances, 2005; 48
8. http://afssaps.sante.fr/htm/10/filltrpsc/lp060304.pdf
9. Comitte on drugs. Neonatal drug withdrawal. Pediatrics 1983; 72: 895-902
10. Grossesse chez les patientes dépendantes aux opiacés. Prescrire 2005; 267: 836-41
11. Swortfiguer D, Cissoko H, Giraudeau B, et al. Neonatal consequences of benzodiazepines used during the last month of pregnancy. Arch Pediatrie 2005; 12: 1327-31
12. Elefant E, Bavoux F, Vauzelle-Gardier C, et al. Psychotropes and pregnancy. J Gynecol Obstet Biol Reprod 2000; 29: 43-51
13. Ostrea EM. Neonatal withdrawal from intrauterine exposure to butalbital. Am J Obstet Gynecol 1982; 143: 597-8
14. Levy M, Spino M. Neonatal withdrawal syndrome: associated drugs and pharmacologic management. Pharmacotherapy 1993; 13: 202-11
15. Budney AJ, Hugues JR, Moore BA, et al. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiat 2004; 161: 1967-77
16. Cissoko H, Swortfiguer D, Giraudeau B, et al. Neonatal outcome after exposure to selective serotonin reuptake inhibitors late in pregnancy. Arch Pediatrie 2005; 12: 1081-4
17. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. New Engl J Med 2006; 354: 579-87
18. Hatch EE, Bracken MB. Effect of marihuana use in pregnancy on fetal growth. Am J Epidemiol 1986; 124: 986-93
19. Fried PA, Watkinson B, Willan A. Marijuana use during pregnancy and decreased length of gestation. Am J Obstet Gynecol 1984; 150: 23-27
20. Association between maternal smoking and low birth weight in Switzerland: the EDEN study. Swiss Med Wkly 2005; 135: 525-30